Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

  • XARELTO® may increase your chance of bleeding. This bleeding can sometimes be serious (and even life-threatening)
  • In studies side effects with XARELTO® included fluid leakage from a wound, itching, pain in arms or legs, blisters, fainting, and muscle spasm
  • Discuss any side effects with your doctor. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (526-7736)

This is a summary of important information about XARELTO®. If you would like more information, talk with your doctor.

Please see full Product Information (http://www.janssenpharmaceuticalsinc.jnj.com/assets/xareltopi.pdf), or visit www.XARELTOhcp.com.

About Janssen Pharmaceuticals, Inc.

As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Pharmaceuticals, Inc., is dedicated to addressing and solving some of the most important unmet medical needs in pain management, infectious diseases and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to individuals with serious conditions, and to physicians throughout the world.

For more information on Janssen Pharmaceuticals, Inc., visit us at www.janssenpharmaceuticalsinc.com or follow us on Twitter at www.twitter.com/JanssenUS.

Dr. Kwong is a paid consultant to Jan
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... N.Y., June 30 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... randomization into its Phase 2b study of Bicifadine,-- a ... of diabetic neuropathic pain. 350 patients were randomized into,the ... expects to,have the last patient complete the study in ...
... Co (NYSE:,LLY) and Boehringer Ingelheim today announced that ... of the European Medicines Agency,(EMEA) has issued a ... for the treatment of Generalised Anxiety,Disorder (GAD)., ... of five clinical studies,-- four double-blind placebo-controlled studies ...
Cached Medicine Technology:XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 2European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 4European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 5European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 6
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... in adults, revs up calorie-burning, experts say , , WEDNESDAY, April ... -- the brown fat revolution, that is. , ... verified that adult humans do possess this "good," slimming form ... and rodents. , The tissue is metabolically active and the ...
... 8 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or ... intra-operative MR held at PLA 301 Hospital in Beijing ... USA, Germany, Taiwan and Hong Kong attended the inaugural ... neurosurgery. The conference was opened by Dir Chen Xiaohong, ...
... Michael Eskew Named New Chair of Audit CommitteeINDIANAPOLIS, April 8 ... (NYSE: LLY ) today announced that J. Michael ... 2009. Mr. Cook, the retired chairman and chief executive officer ... the Lilly board since 2005. Mr. Cook has been a ...
... Serve Health Professionals, Instructors and Counselors , ... Today the American Psychological Association (APA) notified Humanitas, ... stringent criteria to offer continuing education credit hours ... programs. Humanitas offers a variety of educational ...
... Researchers and Updates on Key Discoveries, Plus Panel ... 8 Internationally renowned physician-scientists will discuss the ... plus important recent discoveries in translational cancer research, ... Research Foundation Clinical Investigator Symposium.The April ...
... 8 ORLANDO, Fla., April 8 James ... opening of his new dental practice, DellagioDentist.com, ... Orlando. This new dental practice, located at ... 8.(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CG96485 )Dr. Trantham and ...
Cached Medicine News:Health News:A Fat That May Keep You Thin 2Health News:A Fat That May Keep You Thin 3Health News:Neurosurgeons from around the world gather at PLA 301 Hospital in China 2Health News:J. Michael Cook to Retire from Lilly Board of Directors 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:New Family Dental Practice Opens in Orlando 2
... display of corneal layers: endothelium, ... epithelial layers. Accurate analysis of ... keratocytes, nerve fibres, basal & ... surgery and pathology: optical pachymetry, ...
Ahmed Glaucoma Valve (small size)....
... Long-term biocompatibility is established. Provides a robust ... ensure correct positioning on the globe. Pressure ... which, when covered by Tenons tissue, acts ... postoperative hypotony. The range of implants allows ...
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
Medicine Products: